Main buyer interest
GH and IGF-1 signaling
The blend combines two upstream pathways commonly compared in recovery and body-composition research.
COA VerifiedHormonal Peptides
$65.00
Purchase option
Buy more, save more
Not in stock yet. Leave your email and we will tell you when it is available.
Get notified when it's availableCJC-1295 / Ipamorelin combines a GHRH analogue with a selective ghrelin mimetic and is studied in growth-hormone-secretion, recovery, and body-composition research. For research purposes only.
Orders ship from within Canada in discreet packaging. Express delivery is typically 1–3 business days after dispatch.
Standard returns are not accepted because research materials cannot be safely restocked after delivery. Contact support promptly about damaged, incorrect, or compromised items.
Reconstitution calculator
Enter three known values. The calculator converts the total vial amount and water added into a concentration, then shows the liquid volume and equivalent U-100 syringe units for the quantity entered.
The calculator does not choose a quantity. It converts the quantity you enter. One milligram equals 1,000 micrograms.
Bacteriostatic water is generally the most appropriate choice for multi-use research preparation because it contains a preservative for repeated vial access.
CJC-1295 / Ipamorelin buyer guide
CJC-1295 / Ipamorelin is usually compared by buyers interested in growth-hormone signaling, recovery, sleep, and body-composition research without buying two separate compounds. CJC-1295 acts through the GHRH pathway, while Ipamorelin is a selective growth-hormone secretagogue associated with the ghrelin receptor.
The buying advantage is convenience, but a fixed blend gives up flexibility. The listing states 10mg total material and does not publish the amount of each component, so buyers who need an exact CJC-1295 format or component ratio should verify those details before ordering.
Main buyer interest
The blend combines two upstream pathways commonly compared in recovery and body-composition research.
Human evidence
Small controlled studies found sustained hormone changes in healthy adults using a specific long-acting CJC-1295 format.
Blend advantage
Convenient for a fixed combined product, with less control than separately purchased compounds.
Buyer check
A 10mg total label does not establish a 5mg/5mg split or whether CJC-1295 includes DAC.
Evidence for the individual pathways is stronger than evidence for the exact fixed blend.
| Evidence | Material studied | What was reported | Buyer takeaway |
|---|---|---|---|
| Controlled CJC-1295 studies | Long-acting CJC-1295 with DAC in healthy adults | Sustained increases in GH and IGF-1 | Human hormone evidence, not proof of physique or recovery outcomes |
| Ipamorelin pharmacology | Receptor and animal studies | Selective growth-hormone secretagogue activity | Mechanistic support with limited clinical outcome evidence |
| Combined blend evidence | CJC-1295 plus Ipamorelin | No robust published outcome trials for this exact commercial blend | Benefits and ratio-specific effects remain uncertain |
The CJC-1295 format and component ratio can materially change interpretation. Verify both against the current product documentation.
CJC-1295 mimics growth-hormone-releasing hormone, while Ipamorelin stimulates the growth-hormone secretagogue receptor. The buyer logic is that the two signals may complement one another upstream of growth hormone and IGF-1, which is why the pairing appears in recovery, sleep, and body-composition discussions.
Direct human evidence for this exact combined product is limited. Small CJC-1295 studies showed sustained increases in GH and IGF-1, but the studied drug-affinity-complex version cannot automatically be equated with every product called CJC-1295. Ipamorelin evidence is mainly pharmacology and preclinical work.
The strongest demonstrated human outcome is a hormone-level change, not proven muscle gain, fat loss, sleep improvement, or injury recovery. In healthy-adult trials, the studied long-acting CJC-1295 increased mean GH and IGF-1 for days, but those studies were small and did not establish the broad wellness outcomes often promoted online.
A buyer should therefore treat recovery and body-composition claims as hypotheses downstream of GH and IGF-1 rather than guaranteed results. Changes in IGF-1 can also be clinically important, so people with diabetes, active cancer concerns, pituitary disorders, pregnancy, or medications that affect glucose or hormones need individualized medical assessment.
The products overlap in growth-hormone-axis research but differ in composition and target strategy.
| Product | Composition | Research pathway | Bison format |
|---|---|---|---|
| CJC-1295 / Ipamorelin | Two-component blend | GHRH plus secretagogue pathways | 10mg total |
| Tesamorelin | Single GHRH analogue | GHRH receptor pathway | 5mg, 10mg |
The blend offers two pathways and convenience. Tesamorelin offers a single identified compound with stronger condition-specific visceral-fat evidence. They are not equivalent products.
Choose the blend when convenience and a fixed two-pathway product are the priority. Choose separate compounds when you need to verify the exact CJC-1295 format, control each component independently, or identify which ingredient is associated with an observed response.
Tesamorelin is a single GHRH analogue with stronger condition-specific human evidence for reducing visceral abdominal fat in people with HIV-associated lipodystrophy. CJC-1295 / Ipamorelin has the broader wellness interest, but less direct human outcome evidence for the combined product.
The 10mg label describes total nominal peptide material across both ingredients. It does not mean 10mg of CJC-1295 plus 10mg of Ipamorelin, and it does not prove an equal 5mg/5mg split.
Choose this vial if a ready-made combined product is the goal and the current label or COA provides enough identity detail for your needs. If exact component quantities or the presence of DAC matter, confirm them before purchase or choose separately identified compounds.
The listing identifies independent testing and COA availability. Before ordering, confirm that the available certificate identifies the compound or blend, batch or lot, test date, analytical method, and reported result. After delivery, compare the vial label with that exact documentation rather than relying on a generic certificate.
Identity, purity, fill quantity, sterility, and endotoxin testing answer different questions. A large purity percentage does not prove every other quality attribute, so buyers should check which tests are actually reported and avoid assuming that an unlisted result was performed.
The Bison Peptides CJC-1295 / Ipamorelin vial is supplied as a technical laboratory research material, not an authorized prescription formulation. The page summarizes published research to help buyers understand the compound, evidence, and product format; it is not an individual treatment or dosing recommendation.
Content reviewed August 11, 2026 by the Bison Peptides editorial team.
“I liked being able to purchase CJC-1295 and Ipamorelin together instead of ordering two separate products. The vial arrived securely packaged and clearly identified. The site also made the blend contents easy to understand before ordering. Very straightforward purchase.”
10mg ·
Jordan N. · Verified buyer
“Everything about the order felt professional. The vial came protected inside the shipment and the label clearly listed what was included in the blend. Shipping updates were helpful and the package arrived in great condition. I'd have no hesitation ordering this one again.”
10mg ·
Tyler A. · Verified buyer
“I was mainly looking for a Canadian source carrying this particular combination. Ordering was easy and everything arrived properly sealed. The label and packaging were better than some of the other suppliers I've tried. Overall a positive experience and I would purchase again.”
10mg ·
Eric J. · Verified buyer
The blend is commonly discussed for GH and IGF-1 signaling, recovery, sleep, and body-composition research. Human evidence directly demonstrates hormone changes with a specific CJC-1295 format, while broader outcome claims for the exact blend remain uncertain.
CJC-1295 acts through the GHRH receptor and Ipamorelin through the growth-hormone secretagogue receptor. Combining them creates one fixed product aimed at two upstream signals within the GH axis.
No. The label describes 10mg total blend material. It does not establish a 10mg plus 10mg combination or even an equal 5mg/5mg split.
The product name alone does not answer that. CJC-1295 is used for materials with and without a drug-affinity-complex modification. Buyers who require one format should verify the current label and batch documentation before ordering.
They suit different comparisons. The blend offers two pathways and convenience, while Tesamorelin is a single GHRH analogue with stronger human evidence for visceral-fat reduction in HIV-associated lipodystrophy. Neither is automatically better for every goal.
Choose the blend for a convenient fixed combination. Choose separate compounds when exact component quantities, independent COAs, or the ability to evaluate each ingredient separately matter more.
Ideally it should identify both components, the CJC-1295 format, batch or lot, test date, analytical method, and the reported amount or ratio of each component. A total purity result does not answer every one of those questions.